PTEN Loss (Q28444976)

From Wikidata

Jump to navigation Jump to search

genetic variant

LOSS

Language	Label	Description	Also known as
English	PTEN Loss	genetic variant	LOSS

Statements

Loss Of Function Variant

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/214

human chromosome 10

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/214

89622870

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/214

89731687

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/214

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/214

positive therapeutic predictor for

medical condition treated

prostate cancer

determination method

CIViC evidence level D

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/507

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

medical condition treated

Her2-receptor positive breast cancer

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1297

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

medical condition treated

endometrial cancer

determination method

CIViC evidence level D

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1614

PI3K pathway dependencies in endometrioid endometrial cancer cell lines

medical condition treated

statement disputed by

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5840

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2045

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

statement disputed by

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2074

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

carboplatin / paclitaxel / buparlisib combination therapy

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/714

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.

negative therapeutic predictor for

medical condition treated

Her2-receptor positive breast cancer

statement disputed by

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1386

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

bladder carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/644

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation

determination method

CIViC evidence level B

CIViC 1-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/645

Therapeutic targeting of cancers with loss of PTEN function

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

endometrial cancer

statement disputed by

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/893

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

endometrial cancer

statement disputed by

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/893

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1385

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1492

Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

stomach carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1493

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6315

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2035

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2043

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

determination method

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6271

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

ado-trastuzumab emtansine

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

Her2-receptor positive breast cancer

statement disputed by

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/8706

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

gastric adenocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/864

PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

gastric adenocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/864

PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.

determination method

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/8275

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

negative prognostic predictor for

prostate cancer

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/643

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/214

HGVS nomenclature

no value

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/214

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28444976&oldid=2014801300"